STAVUDINE; LAMIVUDINE; NEVIRAPINE
Clinical safety rating: safe
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
Stavudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase. Lamivudine is an NRTI that inhibits HIV reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV reverse transcriptase, causing enzyme inhibition.
| Metabolism | Stavudine: Intracellular phosphorylation to active triphosphate; undergoes hepatic metabolism via glucuronidation (approximately 40% excreted unchanged in urine). Lamivudine: Intracellular phosphorylation to active triphosphate; undergoes renal excretion (70% unchanged). Nevirapine: Primarily metabolized by CYP3A4 and CYP2B6 to hydroxy metabolites, which are glucuronidated and excreted renally. |
| Excretion | Stavudine: Renal (approximately 60% unchanged) and hepatic metabolism. Lamivudine: Renal (approximately 70% unchanged) via glomerular filtration and active tubular secretion. Nevirapine: Hepatic metabolism (CYP3A4, CYP2B6) followed by renal excretion of metabolites (about 80% in urine, 10% in feces). |
| Half-life | Stavudine: 1.0-1.6 hours (mean ~1.5 h) in adults with normal renal function; prolonged in renal impairment. Lamivudine: 5-7 hours in adults; prolonged in renal impairment. Nevirapine: 25-30 hours (single dose); 40-45 hours with multiple dosing due to autoinduction. |
| Protein binding | Stavudine: <5% bound to plasma proteins. Lamivudine: <36% bound to plasma albumin. Nevirapine: Approximately 60% bound to plasma albumin. |
| Volume of Distribution | Stavudine: 0.5-1.0 L/kg; distributes into total body water. Lamivudine: 1.3-1.5 L/kg; extensive distribution into tissues, including CNS (CSF/plasma ratio ~0.12). Nevirapine: 1.2-1.4 L/kg; wide distribution including CSF (approximately 45% of plasma concentration). |
| Bioavailability | Stavudine: Oral bioavailability >80%. Lamivudine: Oral bioavailability 80-85%. Nevirapine: Oral bioavailability >90%. |
| Onset of Action | Oral administration: Stavudine and Lamivudine: Peak plasma concentrations in 1-1.5 hours; antiviral effect begins within hours. Nevirapine: Peak in 4 hours; onset of antiviral effect within 24-48 hours. |
| Duration of Action | Stavudine: Dosing interval of 12 hours; maintains therapeutic levels for ~12 hours. Lamivudine: Dosing interval of 12 hours; maintains efficacy for 12-24 hours. Nevirapine: Dosing interval of 12 hours after induction; sustained effect due to long half-life. |
| Molecular Weight | Stavudine: 224.21 Da; Lamivudine: 229.26 Da; Nevirapine: 266.30 Da |
One tablet (stavudine 30 mg + lamivudine 150 mg + nevirapine 200 mg) orally twice daily. For patients weighing ≥60 kg, stavudine 40 mg may be used; however, due to toxicity, 30 mg is preferred. Nevirapine requires a 14-day lead-in dose of 200 mg once daily.
| Dosage form | TABLET |
| Renal impairment | If CrCl 26-50 mL/min: administer stavudine 15 mg + lamivudine 150 mg + nevirapine 200 mg every 24 hours. If CrCl <26 mL/min: stavudine and lamivudine are not recommended; nevirapine dosing adjustment not established (consider alternative regimen). |
| Liver impairment | Contraindicated in Child-Pugh class B or C due to nevirapine hepatotoxicity. In Child-Pugh class A: no dose adjustment necessary, but monitor closely. |
| Pediatric use | Weight-based dosing for oral solution: stavudine 1 mg/kg, lamivudine 4 mg/kg, nevirapine 7 mg/kg (lead-in: 4 mg/kg once daily for 14 days) every 12 hours. Maximum doses: stavudine 30 mg/dose, lamivudine 150 mg/dose, nevirapine 200 mg/dose. For children ≥8 years or ≥30 kg, use adult fixed-dose combination tablets adjusted for weight. |
| Geriatric use | No specific dose adjustments solely based on age; however, monitor renal function closely and adjust stavudine and lamivudine doses per CrCl. Elderly are more susceptible to peripheral neuropathy and hepatotoxicity. |
| 1st trimester | Avoid unless benefit outweighs risk. Use only if no alternative due to potential teratogenicity (nevirapine associated with Stevens-Johnson syndrome, lamivudine and stavudine have limited data). |
| 2nd trimester | Use with caution. Monitor for hepatotoxicity (nevirapine) and lactic acidosis (stavudine). |
| 3rd trimester | Use with caution. Increased risk of lactic acidosis with stavudine near term. Nevirapine may cause maternal hepatic events. |
Clinical note
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
| FDA category | Animal |
| Placental transfer | Stavudine: Crosses placenta (cord blood concentrations ~50% maternal); lamivudine: Extensive transfer (cord-maternal ratio ~1.0); nevirapine: Extensive transfer (cord-maternal ratio ~0.5-1.0). |
■ FDA Black Box Warning
Hepatotoxicity: Severe, life-threatening hepatotoxicity, including fatal hepatic events, has been reported. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs. Nevirapine-based therapy should not be initiated in women with CD4+ cell counts >250 cells/mm³ or men with CD4+ cell counts >400 cells/mm³ unless benefit outweighs risk due to increased risk of symptomatic hepatic events.
| Common Effects | Peripheral neuropathy |
| Serious Effects |
Hypersensitivity to any componentConcurrent use with didanosine (increased risk of pancreatitis, lactic acidosis)Severe hepatic impairment (Child-Pugh C) for nevirapine componentLactic acidosis or severe hepatomegaly with steatosis due to stavudinePrevious nevirapine-induced Stevens-Johnson syndrome, toxic epidermal necrolysis, or severe hepatitis
| Precautions | Lactic acidosis/severe hepatomegaly with steatosis; hepatotoxicity including hepatic events; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); immune reconstitution syndrome; pancreatitis (associated with stavudine); peripheral neuropathy (stavudine); lipodystrophy; monitoring of hepatic enzymes and CD4 count. |
Loading safety data…
| Breastfeeding | Stavudine and lamivudine are excreted into breast milk; nevirapine achieves high concentrations. In developed countries, breastfeeding is discouraged due to HIV transmission risk. In resource-limited settings, WHO recommends exclusive breastfeeding while on ART. Monitor infant for toxicity (hepatotoxicity, pancreatitis, neuropathy). |
| Lactation Rating | L3 (Moderately Safe) - Limited data in breastfeeding; use only when benefits outweigh risks. HIV-positive mothers should avoid breastfeeding per standard guidelines. |
| Teratogenic Risk | Stavudine: Crosses placenta; animal studies show embryotoxicity, but human data insufficient. Lamivudine: Low risk; increased early pregnancy loss in animals, not confirmed in humans. Nevirapine: Avoid in first trimester; associated with severe hepatotoxicity and rash; use only if benefit outweighs risk. Overall: Use only if clearly needed in pregnancy; no major human teratogenicity consistently documented. |
| Fetal Monitoring | Monitor maternal liver function (ALT, AST) and skin (nevirapine rash). Fetal ultrasound for growth. Maternal HIV viral load and CD4 count regularly. |
| Fertility Effects | No known significant effects on fertility in humans. Animal studies show no impairment. |
| Food/Dietary | No significant food interactions. Take with or without food. Avoid alcohol due to increased risk of hepatotoxicity with nevirapine. |
| Clinical Pearls | Monitor for hepatotoxicity and severe skin reactions (Stevens-Johnson syndrome) during first 18 weeks of nevirapine therapy. Stavudine carries risk of lactic acidosis and hepatic steatosis. Lamivudine has low genetic barrier to resistance; avoid as monotherapy. Dose adjustments required for renal impairment (CrCl <50 mL/min). Check HLA-B*5701 status before abacavir if switching components. Reconstitute triple-drug fixed-dose combination only if patient is on stable antiretroviral therapy. |
| Patient Advice | Take this medication exactly as prescribed, at the same time each day, with or without food. · Do not miss doses; if you miss a dose within 6 hours, take it as soon as possible. If >6 hours, skip the missed dose and continue regular schedule. · Report any signs of liver problems: yellowing of skin/eyes, dark urine, nausea, vomiting, or abdominal pain. · Seek immediate medical attention for severe skin rash, blisters, or mouth sores, especially in the first 18 weeks of treatment. · This combination does not cure HIV but reduces viral load and transmission risk; practice safe sex and avoid sharing needles. · Monitor for symptoms of peripheral neuropathy (numbness, tingling, pain in hands/feet) and lactic acidosis (unusual muscle pain, difficulty breathing, fatigue). · Tell your doctor about all other medications, including over-the-counter drugs and herbal supplements. |